Anna Harris, MD
Radiation Oncology · Anniston, ALNPI 1780879551
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 51 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 9.7% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for radiation oncology clinicians in AL, where the typical reported total is $993.
Across 51 payments — averaging $21.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$107
- Angiodynamics, Inc.$106
- AstraZeneca$99
- Progenics Pharmaceuticals, Inc.$78
- AbbVie$77
- Novocure Inc.$75
- plus $568 from 19 others
What the payments were for
- Food & beverage$1,110100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 5 | $107 |
| Angiodynamics, Inc. | 1 | $106 |
| AstraZeneca(2 entities) | 5 | $99 |
| Progenics Pharmaceuticals, Inc. | 5 | $78 |
| AbbVie | 4 | $77 |
| Novocure Inc. | 3 | $75 |
| Octapharma USA, Inc. | 3 | $67 |
| Sobi, Inc | 2 | $61 |
| Tersera Therapeutics LLC | 2 | $58 |
| Pharmaessentia USA Corporation | 2 | $39 |
| Johnson & Johnson | 2 | $37 |
| Merck | 2 | $34 |
| Eisai Inc. | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $31 |
| Sanofi | 2 | $29 |
| Incyte Corporation | 1 | $24 |
| Coherus Oncology, Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $20 |
| EMD Serono, Inc. | 1 | $18 |
| Morphosys, US Inc. | 1 | $18 |
| Stemline Therapeutics Inc. | 1 | $18 |
| Genmab U.S., Inc. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Pfizer | 1 | $15 |
| Fortovia Therapeutics, Inc. | 1 | $12 |
How this compares
$1,110 in reported general payments places this provider in the 50th percentile of 87 radiation oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SsdSilver Sulfadiazine | 13 | $380 |
| Tamsulosin Hcl | 15 | $173 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Anniston
- Todd ScarbroughAnniston$898
- Alexander WhitleyMontgomery$441K
- Drexell BoggsBirmingham$35K
- Christopher JahrausAlabaster$28K
- Christopher WilleyBirmingham$13K
- Adam KoleBirmingham$11K
- William HixsonFairhope$10K
- John GleasonHuntsville$9K
- Andrew McDonaldBirmingham$8K
- Hoyt ChildsHuntsville$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.